stockchase picture

Compiling comments that experts make about stocks while on public TV.

Company Index

List by Company Name

List by Symbol

Abbott Labs Stock Symbol: ABT-N

Last Price Recorded: 42.2400 on 2014-09-01 01:14:01

Globe 200 day average
Google Discussions (view only)
yahoo discussion
Bloomberg
Date Signal Expert Opinion Price
2012-04-19 BUY Stan Wong This is a more of a growth company in the healthcare space. You are looking at higher single-digit growth and you are getting it for around 11-12 times PE. Nice dividend at around 3.4%.
Price:
$59.510
Subject:
NORTH AMERICAN - LARGE & ETFs
Bias:
CAUTIOUS
Owned:
No
2012-03-15 TOP PICK Gavin Graham Splitting itself into two businesses – Pharma and Infant nutrition. Couple of interesting acquisitions in the last year and a half. 3.6% yield.
Price:
$59.110
Subject:
NORTH AMERICAN - LARGE & GLOBAL EQUITIES
Bias:
DEFENSIVE
Owned:
Yes
2012-02-09 BUY Brian Acker, CA Has Merck and Pfizer. There was no time when you could buy it this cheaply except for the August correction.
Price:
$55.260
Subject:
NORTH AMERICAN - LARGE
Bias:
BULLISH
Owned:
No
2011-11-29 BUY on WEAKNESS Norman Levine Fundamentally he likes it. Operationally it is performing as it should. They are tied into the European economy and people are worried about the EU economies, although their sales are holding up. Getting hurt by tax-loss selling.
Price:
$53.050
Subject:
NORTH AMERICAN - LARGE
Bias:
DEFENSIVE
Owned:
Unknown
2011-10-24 COMMENT Norman Levine Likes health care companies generally because they’re defensive. Splitting their drug company from the rest of the company. Likes this as you get pure plays.
Price:
$53.450
Subject:
NORTH AMERICAN - LARGE
Bias:
CAUTIOUS
Owned:
No
2011-10-24 SELL ON STRENGTH Gordon Reid Half of business in Pharma space and rest is in nutritional area.
Price:
$53.450
Subject:
US EQUITIES
Bias:
DEFENSIVE
Owned:
No
2011-10-20 BUY Barry Schwartz Restructuring came as a big surprise. Good valuation at 10X earnings. Long track record of raising dividends. Only real competition is Johnson & Johnson (JNJ-N) but feels this one has better growth. If they do the spinoff, they will probably stick with the non-pharma side of the business, which will be the better growth.
Price:
$54.050
Subject:
NORTH AMERICAN - LARGE
Bias:
UNKNOWN
Owned:
Yes
2011-10-19 HOLD Stan Wong The market likes the split. Going to split into pharma and medical space. 3.6% dividend. Hold on to it for the time being.
Price:
$53.250
Subject:
NORTH AMERICAN - LARGE & ETFs
Bias:
DEFENSIVE
Owned:
No
2011-09-14 BUY Barry Schwartz Diversified Pharma with pharmaceuticals, nutritionals and medical devices. Trading at a lower valuation (11X earnings) with a higher dividend and better growth prospects than Johnson & Johnson (JNJ-N).
Price:
$50.920
Subject:
NORTH AMERICAN - LARGE
Bias:
DEFENSIVE
Owned:
Yes
2011-08-31 BUY Gordon Reid Have grown earnings every single year since 1991. Only 10 or 11x earnings. Likes them in the health care space because they are diversified. Market is worried about their largest drug, whose patent expires in a few years. He doesn’t see it as a problem.
Price:
$21.270
Subject:
US EQUITIES
Bias:
CAUTIOUS
Owned:
Yes
2011-08-02 PAST TOP PICK Christine Poole (A Top Pick July 26/10. Up 5.72%.) Diversified healthcare company. Branded drug division has Marot for arthritis etc., medical devices including stents and nutritional. Have also been making acquisitions in the branded generic space. Good diversity. About 20% of revenues come from emerging markets.
Price:
$50.200
Subject:
NORTH AMERICAN - LARGE
Bias:
OPTIMISTIC
Owned:
Yes
2011-07-08 DON'T BUY Brian Acker, CA He has a model price of $57.97, an 8% upside. Good company but he sees a lot of value elsewhere.
Price:
$53.330
Subject:
NORTH AMERICAN - LARGE (OIL/GAS)
Bias:
UNKNOWN
Owned:
No
2011-05-24 BUY Barry Schwartz Raised dividend 30+ years in a row. Is going to show 10% earnings growth over next 2-3 years. A good space. They got too cheap so there is an opportunity.
Price:
$53.330
Subject:
NORTH AMERICAN - LARGE
Bias:
OPTIMISTIC
Owned:
Unknown
2011-05-03 TOP PICK Barry Schwartz All different types of health care services and products. 11 times this year’s earnings. Nice valuation and entry point here.
Price:
$52.850
Subject:
NORTH AMERICAN - LARGE
Bias:
SELECTIVE
Owned:
Yes
2011-05-02 PAST TOP PICK Christine Poole (A Top Pick April 26/10. Up 8.35%.) Have both generic and branded drug divisions. Making acquisitions to increase their emerging market exposure, which currently represent 25% of their revenues. Also has the number one share in the drug alluding stent business. Very strong nutritional business.
Price:
$52.590
Subject:
NORTH AMERICAN - LARGE
Bias:
OPTIMISTIC
Owned:
Yes
Showing 46 to 60 of 82 entries

No Comments.


You must be logged in to comment.